| Literature DB >> 34550684 |
P Reboredo-Rodríguez1, L Olmo-García2, M Figueiredo-González1, C González-Barreiro1, A Carrasco-Pancorbo2, B Cancho-Grande1.
Abstract
The INFOGEST standardized method was applied to assess the potential bioaccessibility and bioaccessibility of the phenolic compounds from a Galician extra-virgin olive oil (EVOO). The in vitro digestion model involves three steps and generates two fractions after each one: an aqueous fraction (namely, water phase (Wp)) and an oily fraction (namely, oily phase (Op)). The results showed that secoiridoids were the most abundant family in the Galician EVOO polar fraction, representing 98% of the total phenolic compounds. After oral digestion, phenolic acids and simple phenols were mainly detected in Wp, while lignans and flavonoids were mostly found in Op. After gastric digestion, extensive hydrolysis of secoiridoids was observed to generate free tyrosol, hydroxytyrosol, and hydroxytyrosol acetate. The instability of secoiridoids after intestinal digestion was again responsible for the release of simple phenols, which were mainly recovered in Wp together with flavonoids. In contrast, lignans were stable to duodenal conditions and remained in Op.Entities:
Keywords: antioxidant capacity; bioaccessibility; extra-virgin olive oil; in vitro digestion; phenolic compounds; α-glucosidase inhibition
Mesh:
Substances:
Year: 2021 PMID: 34550684 PMCID: PMC8929668 DOI: 10.1021/acs.jafc.1c04592
Source DB: PubMed Journal: J Agric Food Chem ISSN: 0021-8561 Impact factor: 5.279
Figure 1Schematic of the experiments including the fractions collected after each digestion stage and the performed determinations. Nomenclature: oily phase (Op); water phase (Wp).
Phenolic Compounds Determined in the Two Fractions (Op and Wp) (mg/kg of EVOO) after In Vitro Digestion (Oral, Gastric, and Intestinal) of Galician EVOO (mg/kg of EVOO)a
| oily
phase (Op) | water
phase (Wp) | |||||||
|---|---|---|---|---|---|---|---|---|
| phenolic compounds | EVOO | oral step | gastric step | intestinal step | oral step | gastric step | intestinal step | potential bioaccesibility (%) |
| oleuropein derivatives | ||||||||
| DOA | 301.40 ± 13.04 | 113.58 ± 14.66 | 5.49 ± 0.23 | n.d. | 172.97 ± 6.84 | 5.91 ± 0.57 | n.d. | |
| OlAgl (Is I) | 1.25 ± 0.11 | 8.38 ± 1.27 | 0.82 ± 0.28 | n.d. | 8.26 ± 0.68 | n.d. | n.d. | |
| OlAgl (main peak) | 80.33 ± 2.82 | 80.88 ± 6.56 | 52.07 ± 3.33 | 2.16 ± 0.80 | 22.59 ± 1.54 | 38.64 ± 4.81 | 0.68 ± 0.72 | 0.8 |
| OlAgl (Is II) | 13.40 ± 1.83 | 13.60 ± 1.46 | 5.19 ± 0.26 | n.d. | 5.36 ± 0.35 | 0.64 ± 0.04 | n.d. | |
| 396.38 | 216.44 | 63.57 | 2.16 | 209.18 | 45.19 | 0.68 | ||
| ligstroside derivatives | ||||||||
| DLA | 515.11 ± 17.02 | 289.80 ± 45.92 | 37.65 ± 4.74 | n.d. | 112.45 ± 8.34 | 1.86 ± 0.28 | n.d. | |
| LigAgl (Is I) | 16.41 ± 0.35 | 39.71 ± 2.03 | 11.18 ± 1.09 | n.d. | 15.23 ± 1.77 | n.d. | n.d. | |
| LigAgl (Main peak) | 234.08 ± 22.30 | 112.90 ± 0.80 | 47.60 ± 4.38 | 5.64 ± 0.70 | 15.54 ± 1.56 | 8.01 ± 0.88 | n.d. | |
| LigAgl (Is IV) | 51.73 ± 6.22 | 48.02 ± 1.72 | 19.43 ± 1.47 | n.d. | 12.40 ± 0.87 | n.d. | n.d. | |
| 817.33 | 490.43 | 115.86 | 5.64 | 155.62 | 9.87 | |||
| simple phenols | ||||||||
| O-HTy | 0.05 ± 0.01 | n.d. | n.d. | n.d. | 0.07 ± 0.01 | n.d. | n.d. | |
| HTy | 6.22 ± 0.23 | 0.45 ± 0.02 | 0.61 ± 0.03 | 0.047 ± 0.001 | 12.44 ± 0.65 | 8.38 ± 0.48 | 18.79 ± 0.38 | 302 |
| Ty | 4.95 ± 0.21 | 0.48 ± 0.05 | 0.57 ± 0.20 | n.d. | 6.43 ± 0.26 | 3.82 ± 0.47 | 8.51 ± 1.07 | 172 |
| HTy-Ac | 0.29 ± 0.02 | 0.05 ± 0.03 | 0.16 ± 0.08 | 1.95 ± 0.29 | 0.67 ± 0.04 | 6.87 ± 0.86 | 12.14 ± 1.06 | 4186 |
| 11.51 | 0.98 | 1.34 | 2.00 | 19.61 | 19.07 | 39.44 | ||
| phenolic acids | ||||||||
| GA | 0.51 ± 0.04 | 0.02 ± 0.01 | n.d. | n.d. | 0.59 ± 0.08 | 0.24 ± 0.02 | n.d. | |
| Van | 0.21 ± 0.02 | n.d. | 0.08 ± 0.01 | n.d. | 0.21 ± 0.03 | 0.07 ± 0.01 | n.d. | |
| 0.19 ± 0.01 | n.d. | 0.04 ± 0.01 | n.d. | 0.15 ± 0.01 | 0.028 ± 0.002 | n.d. | ||
| 0.91 | 0.02 | 0.12 | 0.95 | 0.34 | ||||
| flavonoids | ||||||||
| Lut | 3.80 ± 0.43 | 2.03 ± 0.15 | 2.24 ± 0.11 | 0.85 ± 0.10 | 1.06 ± 0.12 | 0.54 ± 0.04 | 2.04 ± 0.20 | 54 |
| Api | 0.79 ± 0.08 | 0.60 ± 0.05 | 0.57 ± 0.04 | 0.39 ± 0.06 | 0.036 ± 0.004 | 0.022 ± 0.002 | 0.18 ± 0.01 | 23 |
| Dios | 0.38 ± 0.05 | 0.33 ± 0.02 | 0.31 ± 0.02 | 0.21 ± 0.03 | 0.02 ± 0.01 | 0.002 ± 0.001 | 0.10 ± 0.02 | 26 |
| 4.97 | 2.96 | 3.12 | 1.45 | 1.12 | 0.56 | 2.32 | ||
| lignans | ||||||||
| Syr | 0.043 ± 0.004 | 0.09 ± 0.01 | 0.072 ± 0.004 | 0.025 ± 0.003 | 0.05 ± 0.01 | 0.09 ± 0.01 | n.d. | |
| Pin | 1.81 ± 0.10 | 1.64 ± 0.09 | 1.20 ± 0.06 | 0.80 ± 0.08 | 0.173 ± 0.004 | 0.29 ± 0.04 | 0.46 ± 0.06 | 25 |
| Ac-Pin | 0.17 ± 0.01 | 0.13 ± 0.01 | 0.09 ± 0.01 | 0.056 ± 0.005 | 0.036 ± 0.002 | 0.06 ± 0.01 | 0.10 ± 0.01 | 59 |
| 2.02 | 1.86 | 1.36 | 0.88 | 0.26 | 0.44 | 0.56 | ||
| total phenolic compounds | 1233.12 | 712.69 | 185.37 | 12.13 | 386.74 | 75.47 | 43.00 | |
| Nonphenolic But Structurally Related Compounds | ||||||||
| elenolic acid derivatives | ||||||||
| DEA | 3.54 ± 0.46 | 0.10 ± 0.04 | n.d. | n.d. | 3.82 ± 0.42 | 2.21 ± 0.32 | 0.71 ± 0.09 | 20 |
| Desoxy-EA | 113.76 ± 14.42 | 21.42 ± 2.68 | 8.75 ± 1.19 | 0.46 ± 0.09 | 50.82 ± 3.74 | 28.65 ± 2.58 | 6.88 ± 1.17 | 6.0 |
| Hy-EA | 0.43 ± 0.07 | n.d. | n.d. | n.d. | 0.37 ± 0.06 | 0.14 ± 0.09 | 0.29 ± 0.06 | 67 |
| EA | 356.21 ± 27.12 | 11.36 ± 1.24 | 8.877 ± 0.002 | n.d. | 274.04 ± 35.27 | 12.17 ± 0.30 | n.d. | |
| 473.94 | 32.88 | 17.63 | 0.46 | 329.05 | 43.17 | 7.88 | ||
Abbreviations: DOA: dialdehydic form of decarboxymethyl oleuropein aglycone or dialdehydic form of decarboxymethyl elenolic acid linked to hydroxytyrosol or oleacein; OlAgl (main peak): oleuropein aglycone (main peak); OlAgl (Is I): oleuropein aglycone (isomer I); OlAgl (Is II): oleuropein aglycone (isomer II); DLA: dialdehydic form of decarboxymethyl ligstroside aglycone or dialdehydic form of decarboxymethyl elenolic acid linked to tyrosol or oleocanthal; LigAgl (main peak): ligstroside aglycone (main peak); LigAgl (Is I): ligstroside aglycone (isomer I); LigAgl (Is IV): ligstroside aglycone (isomer IV); O-HTy: oxidized hydroxytyrosol; HTy: hydroxytyrosol or 3,4-dihydroxyphenylethanol; Ty: tyrosol or p-hydroxyphenylethanol; HTy-Ac: hydroxytyrosol acetate; Van: vanillic acid; p-Cou: p-coumaric acid; Lut: luteolin; Api: apigenin; Dios: diosmetin; Syr: syringaresinol; Pin: pinoresinol; Ac-Pin: acetoxypinoresinol; DEA: decarboxymethylated form of elenolic acid or dialdehydic form of decarboxymethyl of elenolic acid; Desoxy-EA: Desoxy elenolic acid; Hy-EA: hydroxy elenolic acid or hydroxylated form of elenolic acid; EA: elenolic acid.
Lut, Api, and Dios were determined by DAD (λ = 330 nm).
Pin and Ac-Pin were determined by FLD (280–328).
Figure 2Total phenolic compounds (TPC), o-diphenols, and antioxidant capacity (AC) of Galician EVOO before in vitro digestion (MeOH extract) and after in vitro digestion (oral digestion, gastric digestion, intestinal digestion, and intestinal digestion + dialysis membrane). GAE: gallic acid equivalents; TE: Trolox equivalents. It has not been possible to determine the AC in the oily phase of the intestinal digestion and the intestinal digestion + dialysis membrane.
Phenolic Compounds (μg Phenolic Compound in Each Fraction) Determined in the Dialyzed Fraction (Bioaccessibility) and in the Wp and Op (Fraction Directed to Colon) after In Vitro Digestion of Galician EVOO as Measured by LC–DAD/FLD/MSa
| bioaccessibility | fractions
to colon | |||||
|---|---|---|---|---|---|---|
| phenolic compounds | EVOO | dialyzed fraction (μg) | % | Wp (μg) | Op (μg) | % |
| oleuropein derivatives | ||||||
| OlAgl (main peak) | 401.65 ± 14.10 | 1.22 ± 0.13 | 0.3 | 13.94 ± 0.67 | 21.03 ± 2.55 | 8.7 |
| simple phenols | ||||||
| HTy | 31.10 ± 1.14 | 19.83 ± 0.98 | 64 | 64.78 ± 5.80 | 0.006 ± 0.005 | 208 |
| Ty | 24.77 ± 1.05 | 8.61 ± 0.54 | 35 | 29.87 ± 1.09 | n.d. | 121 |
| HTy-Ac | 1.47 ± 0.12 | 13.46 ± 0.42 | 916 | 50.13 ± 5.28 | 5.95 ± 0.81 | 3815 |
| flavonoids | ||||||
| Lut | 19.02 ± 2.15 | 0.54 ± 0.04 | 2.8 | 12.41 ± 2.29 | 2.39 ± 0.37 | 78 |
| Api | 3.94 ± 0.39 | 0.06 ± 0.01 | 1.5 | 1.29 ± 0.04 | 1.38 ± 0.17 | 68 |
| Dios | 1.90 ± 0.27 | 0.06 ± 0.01 | 3.2 | 0.13 ± 0.07 | 0.55 ± 0.06 | 36 |
| lignans | ||||||
| Pin | 9.03 ± 0.49 | 0.81 ± 0.09 | 9.0 | 2.10 ± 0.07 | 2.39 ± 0.31 | 50 |
| Ac-Pin | 0.85 ± 0.03 | 0.12 ± 0.02 | 14 | 0.46 ± 0.01 | 0.22 ± 0.03 | 80 |
| Nonphenolic But Structurally Related Compounds | ||||||
| elenolic acid derivatives | ||||||
| DEA | 17.68 ± 2.30 | n.d. | 4.12 ± 0.21 | n.d. | 23 | |
| Desoxy-EA | 568.81 ± 72.12 | 5.52 ± 0.87 | 1.0 | 27.67 ± 2.21 | 1.12 ± 0.16 | 5.1 |
| Hy-EA | 2.17 ± 0.34 | 0.02 ± 0.01 | 1.0 | 0.02 ± 0.01 | n.d. | 0.9 |
Abbreviations: OlAgl (main peak): oleuropein aglycone (main peak); HTy: hydroxytyrosol or 3,4-dihydroxyphenylethanol; Ty: tyrosol or p-hydroxyphenylethanol; HTy-Ac: hydroxytyrosol acetate; Lut: luteolin; Api: apigenin; Dios: diosmetin; Pin: pinoresinol; Ac-Pin: acetoxypinoresinol; DEA: decarboxymethylated form of elenolic acid or dialdehydic form of decarboxymethyl of elenolic acid; Desoxy-EA: Desoxy elenolic acid; Hy-EA: Hydroxy elenolic acid or hydroxylated form of elenolic acid.
Lut, Api, and Dios were determined by DAD (λ = 330 nm).
Pin and Ac-Pin were determined by FLD (280–328).
Figure 3Bioaccessibility (%) and fraction directed to colon (%) of oleuropein derivatives, simple phenols, flavonoids, lignans, and elenolic acid derivatives in the Galician EVOO after in vitro digestion as determined by LC–DAD/FLD/MS. OlAgl (main peak): oleuropein aglycone (main peak); HTy: hydroxytyrosol or 3,4-dihydroxyphenylethanol; Ty: tyrosol or p-hydroxyphenylethanol; HTy-Ac: hydroxytyrosol acetate; Lut: luteolin; Api: apigenin; Dios: diosmetin; Pin: pinoresinol; Ac-Pin: acetoxypinoresinol; DEA: decarboxymethylated form of elenolic acid or dialdehydic form of decarboxymethyl of elenolic acid; Desoxy-EA: Desoxy elenolic acid; Hy-EA: hydroxy elenolic acid or hydroxylated form of elenolic acid.
Figure 4IC50 values (μg of dry extract/mL) of the EVOO, the bioaccessible fraction, and the acarbose (positive control, μg/mL) against α-glucosidase enzyme involved in type 2 diabetes.